Hepatitis Flashcards
Diagnosing Hep A?
based on positive IgM antibodies to the hepatitis A virus and symptoms
The presence of IgM antibody to the hepatitis A virus indicates an acute infection.
Symptoms of Hep A?
Constitutional. Nausea, vomiting, fever, fatigue
Treatment for Hep A
No antiviral treatment exists for the hepatitis A infection.
Treatment is only supportive, and symptoms resolve spontaneously in the majority of patients as the illness is self-limiting. Therefore, the patient should be reassured that his symptoms will most likely resolve spontaneously.
Window period?
where they have cleared HBsAg from the blood, but anti-HBs has not yet appeared. This patient can still have hepatitis B infection despite testing negative for HBsAg and anti-HBs.
The first antibody to appear after hepatitis B infection is
immunoglobulin M (IgM) antibody to hepatitis B core antigen (HBcAg).
The presence of IgM anti-HBc also means that the patient has an acute hepatitis B virus infection and is required to make the diagnosis. Once the IgM anti-HBc disappears in a few weeks, IgG anti-HBc is detected which usually remains present for life.
High-risk groups for HCV infection
IV drug users (especially long-time users)
Hepatitis B virus (HBV) or HIV-positive individuals
Prisoners
Recipients of blood transfusions or organ transplants before 1992 (Testing of donor blood was introduced in 1992)
Serology of resolved hepatitis C infection
If the infection has cleared or has been successfully treated, HCV RNA cannot be detected and transaminases return to normal levels. However, anti-HCV IgG antibodies persist indicating previous infection.
Chronic hep C treatment goals
Complete cure. Response rates may be as high as 95%, especially in patients without liver cirrhosis.
Eradication of HCV RNA in serum as defined by SVR (sustained virologic response)
SVR is present if no HCV RNA is detectable in the patient’s serum 6 months after completion of antiviral treatment.
Chronic Hep C treatment
Chosen based on viral genotype, history of antiviral treatment, and degree of liver fibrosis
Combination of two direct-acting antivirals (DAAs)
Sofosbuvir + velpatasvir for 12 weeks (all 6 genotypes)
Acute hepatitis C treatment
Goal: prevent transition to chronic infection!
Treatment: interferon-α or peginterferon-α (PEG-INF) for 6 months
Hep C complications
Rarely fulminant hepatitis (liver failure)
Liver cirrhosis
Hepatocellular carcinoma
Secondary hemochromatosis
Signs/symptoms of high bilirubin
Yellowing of skin and sclera
Clay-colored stools
Dark urine
Hep C transmission
Blood transfusions, IV drug use, rarely sexual
Treatment for chronic hep B
Interferon, lamivudine
Acute Hep C diagnosis (active)
Anti-Hep C antibody
Positive Hep C RNA assay